A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 18 Oct 2017 Hiroshi Handa, M.D. is a lead investigator from Maebashi-city, Gunma, Japan.
    • 13 Oct 2017 Planned End Date changed from 3 Jan 2019 to 8 Jul 2019.
    • 13 Oct 2017 Planned primary completion date changed from 1 Feb 2018 to 30 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top